12:00 AM
 | 
Mar 30, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Byetta exenatide endocrine data

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), San Diego, Calif.
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Product: Byetta exenatide
Business: Endocrine
Molecular target: Glucagon-like peptide-1 receptor (GLP1R)
Description: Synthetic exendin-4
Indication: Treat Type II diabetes
Endpoint: Cardiovascular events including CV mortality,...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >